Laminectomy Adjacent to Instrumented Fusion Increases Adjacent Segment Disease.

STUDY

DESIGN

Retrospective cohort.

OBJECTIVE

To determine if performing a simultaneous laminectomy at an unfused level adjacent to an instrumented fusion increases the risk of adjacent segment disease (ASD).

SUMMARY OF BACKGROUND DATA: Laminectomy adjacent to instrumented fusion has uncertain outcomes. The increased mechanical forces at the unfused laminectomy may lead to more ASD. Few studies have examined the development of ASD with regard to laminectomy performed adjacent to instrumented fusions.

MATERIALS AND

METHODS

Seven hundred eighty-nine patients underwent instrumented lumbar fusion and laminectomy at the same level(s) (n=676) or with an additional adjacent level laminectomy (n=113) with a minimum of 2-year follow-up. Diagnoses were degenerative spondylosis (n=241), degenerative spondylolisthesis (n=485), and isthmic spondylolisthesis (n=63) in addition to central stenosis. Primary outcome measures included development of ASD, time to development of ASD, revision surgery, and time to revision surgery.

RESULTS

The adjacent laminectomy group developed ASD at a significantly greater rate of 57.5% (n=65), compared with 35.2% (n=238) of the nonadjacent laminectomy group ( P <0.001). The revision surgery rate was also greater in the adjacent laminectomy group (22.1% vs. 13.5%, P <0.001). There was no difference in time to revision surgery (31.1 vs. 32.6 mo, P =0.71) or time to ASD development (31.2 vs. 32.3 mo, P =0.72). ODI and VAS scores did not differ, nor did patient baseline demographics including sex, BMI, Charleston Comorbidity Index, and tobacco use. The exception was the average age of the adjacent laminectomy group was 67.6 years while the average age of the nonadjacent laminectomy group was 62.3 years ( P <0.001). However, age was not found to be an independent predictor of ASD development ( P =0.44).

CONCLUSION

Surgeons should be cautious when performing a laminectomy adjacent to an instrumented fusion, as this increases the rate of ASD as well as revision surgery.

LEVEL OF EVIDENCE: Therapeutic Level-II.